Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Die Pathologie
Erschienen in: Der Pathologe 1/2013

01.02.2013 | Schwerpunkt

Lymphknotenpathologie – ein Update

verfasst von: Dr. S. Hartmann, M.L. Hansmann

Erschienen in: Die Pathologie | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine krankheitsbedingte oder iatrogene Immunsuppression stellt einen erheblichen Risikofaktor dar, ein malignes Lymphom zu entwickeln. Der medizinische Fortschritt mit Organtransplantationen, erfolgreicher Behandlung von Autoimmunerkrankungen oder einer verbesserten HIV-Therapie bedingt die Zunahme immunsupprimierter Patienten. Verschiedene Formen der Immunsuppression und jeweils typische Lymphomentitäten werden im vorliegenden Artikel erörtert. Einen zweiten Schwerpunkt dieses Updates bilden Grauzonenlymphome zwischen Hodgkin-Lymphom und diffusem großzelligem B-Zell-Lymphom. Diese Kategorie stellt nicht nur ein diagnostisches Problem dar, sondern entspricht vielmehr einem biologischen Kontinuum.
Literatur
1.
Penn I, Hammond W, Brettschneider L et al (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1:106–112PubMed
2.
Evens AM, Roy R, Sterrenberg D et al (2010) Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep 12:383–394PubMedCrossRef
3.
Loren AW, Porter DL, Stadtmauer EA et al (2003) Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 31:145–155PubMedCrossRef
4.
Meij P, Esser JW van, Niesters HG et al (2003) Impaired recovery of Epstein-Barr virus (EBV)–specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101:4290–4297PubMedCrossRef
5.
Dotti G, Fiocchi R, Motta T et al (2002) Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 74:1095–1102PubMedCrossRef
6.
Cockfield SM (2001) Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3:70–78PubMedCrossRef
7.
Bollard CM, Rooney CM, Heslop HE (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9:510–519PubMedCrossRef
8.
Nalesnik MA (2001) The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 3:88–96PubMedCrossRef
9.
Knowles DM, Cesarman E, Chadburn A et al (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552–565PubMed
10.
Shaknovich R, Basso K, Bhagat G et al (2006) Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica 91:1313–1320PubMed
11.
Gulley ML, Swinnen LJ, Plaisance KT Jr et al (2003) Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 76:959–964PubMedCrossRef
12.
Reshef R, Vardhanabhuti S, Luskin MR et al (2011) Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(bigstar). Am J Transplant 11:336–347PubMedCrossRef
13.
Trappe R, Oertel S, Leblond V et al (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13:196–206PubMedCrossRef
14.
Haque T, Wilkie GM, Jones MM et al (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110:1123–1131PubMedCrossRef
15.
Ciceri F, Bonini C, Stanghellini MT et al (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10:489–500PubMedCrossRef
16.
Di Stasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673–1683CrossRef
17.
Küppers R (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3:801–812PubMedCrossRef
18.
Ferreri AJ, Govi S, Pileri SA (2012) Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol 83:283–292PubMedCrossRef
19.
Travert M, Huang Y, de Leval L et al (2012) Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 119:5795–5806PubMedCrossRef
20.
Cooke CB, Krenacs L, Stetler-Stevenson M et al (1996) Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 88:4265–4274PubMed
21.
Schafer E, Chen A, Arceci RJ (2009) Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant. Pediatr Blood Cancer 53:1127–1129PubMedCrossRef
22.
Konuma T, Ooi J, Takahashi S et al (2007) Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 48:630–632PubMedCrossRef
23.
Biggar RJ, Jaffe ES, Goedert JJ et al (2006) Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108:3786–3791PubMedCrossRef
24.
Bohlius J, Schmidlin K, Boue F et al (2011) HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. Blood 117:6100–6108PubMedCrossRef
25.
Audouin J, Diebold J, Pallesen G (1992) Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin’s disease in HIV-positive patients. J Pathol 167:381–384PubMedCrossRef
26.
Pelstring RJ, Zellmer RB, Sulak LE et al (1991) Hodgkin’s disease in association with human immunodeficiency virus infection. Pathologic and immunologic features. Cancer 67:1865–1873PubMedCrossRef
27.
Thompson LD, Fisher SI, Chu WS et al (2004) HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol 121:727–738PubMedCrossRef
28.
Bosch Princep R, Lejeune M, Salvado Usach MT et al (2005) Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin’s lymphoma. Ann Hematol 84:661–666CrossRef
29.
Kiyasu J, Aoki R, Tanaka PY et al (2012) FOXP3(+) regulatory and TIA-1(+) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma. Pathol Int 62:77–83PubMedCrossRef
30.
Muller-Hermelink HK, Kaiserling E, Sonntag HG (1982) Modulation of epithelioid cell granuloma formation to apathogenic mycobacteria by cyclosporin A. Pathol Res Pract 175:80–96PubMedCrossRef
31.
Muller H, Takeshita M (1991) In situ immunophenotype of macrophages and lymphocytes in granuloma formation of tuberculous lymphadenitis in HIV-infected and immunocompetent patients. Res Virol 142:159–172PubMedCrossRef
32.
Hansch HC, Smith DA, Mielke ME et al (1996) Mechanisms of granuloma formation in murine Mycobacterium avium infection: the contribution of CD4+ T cells. Int Immunol 8:1299–1310PubMedCrossRef
33.
Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362:875–885PubMedCrossRef
34.
Tzankov A, Matter MS, Dirnhofer S (2010) Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 77:301–308PubMedCrossRef
35.
Kamper P, Bendix K, Hamilton-Dutoit S et al (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica 96:269–276PubMedCrossRef
36.
Tan KL, Scott DW, Hong F et al (2012) Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120:3280–3287PubMedCrossRef
37.
38.
Swerdlow SH, International Agency for Research on Cancer, World Health Organization (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Aufl. International Agency for Research on Cancer. Lyon, France
39.
Joos S, Kupper M, Ohl S et al (2000) Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549–552PubMed
40.
Weniger MA, Gesk S, Ehrlich S et al (2007) Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 46:406–415PubMedCrossRef
41.
Joos S, Otano-Joos MI, Ziegler S et al (1996) Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87:1571–1578PubMed
42.
Joos S, Menz CK, Wrobel G et al (2002) Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 99:1381–1387PubMedCrossRef
43.
Hartmann S, Martin-Subero JI, Gesk S et al (2008) Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma by array-based comparative genomic hybridization. Haematologica 93:1318–1326PubMedCrossRef
44.
Baus D, Pfitzner E (2006) Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer 15:1404–1413CrossRef
45.
Melzner I, Bucur AJ, Bruderlein S et al (2005) Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105:2535–2542PubMedCrossRef
46.
Weniger MA, Melzner I, Menz CK et al (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25:2679–2684PubMedCrossRef
47.
Renné C, Willenbrock K, Küppers R et al (2005) Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 105:4051–4059PubMedCrossRef
48.
Renné C, Willenbrock K, Martin-Subero JI et al (2007) High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21:780–787PubMedCrossRef
49.
Eberle FC, Rodriguez-Canales J, Wei L et al (2011) Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558–566PubMedCrossRef
50.
Zamo A, Malpeli G, Scarpa A et al (2005) Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. Mod Pathol 18:1448–1453PubMedCrossRef
51.
Hoeller S, Zihler D, Zlobec I et al (2010) BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B-cell lymphoma. Histopathology 56:217–228PubMedCrossRef
52.
Barth TF, Leithauser F, Joos S et al (2002) Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 3:229–234PubMedCrossRef
53.
Oschlies I, Burkhardt B, Salaverria I et al (2010) Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 96:262–268PubMedCrossRef
54.
Dunleavy K, Grant C, Eberle FC et al (2012) Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep 7:241–247PubMedCrossRef
55.
Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMedCrossRef
56.
Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947PubMedCrossRef
57.
Ott G, Ziepert M, Klapper W et al (2010) Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116:4916–4925PubMedCrossRef
58.
Ott MM, Horn H, Kaufmann M et al (2012) The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients. Leuk Res 36:544–545PubMedCrossRef
59.
Benesova K, Forsterova K, Votavova H et al (2013) The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma 60:68–73PubMedCrossRef
60.
Castillo JJ, Beltran BE, Song MK et al (2012) The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 36:413–417PubMedCrossRef
61.
Hummel M, Bentink S, Berger H et al (2006) A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419–2430PubMedCrossRef
62.
Leucci E, Cocco M, Onnis A et al (2008) MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 216:440–450PubMedCrossRef
63.
Boerma EG, Siebert R, Kluin PM et al (2009) Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 23:225–234PubMedCrossRef
64.
Lin P, Dickason TJ, Fayad LE et al (2012) Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 118:1566–1573PubMedCrossRef
65.
Salaverria I, Siebert R (2011) The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 29:1835–1843PubMedCrossRef
66.
67.
Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452–3459PubMedCrossRef
68.
Boudova L, Torlakovic E, Delabie J et al (2003) Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 102:3753–3758PubMedCrossRef
69.
Fan Z, Natkunam Y, Bair E et al (2003) Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27:1346–1356PubMedCrossRef
70.
Achten R, Verhoef G, Vanuytsel L et al (2002) T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 20:1269–1277PubMedCrossRef
71.
Brune V, Tiacci E, Pfeil I et al (2008) Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 205:2251–2268PubMedCrossRef
72.
Churchill HR, Roncador G, Warnke RA et al (2010) Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Hum Pathol 41:1726–1734PubMedCrossRef
73.
Van Loo P, Tousseyn T, Vanhentenrijk V et al (2010) T cell/histiocyte rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 95:440–448CrossRef
74.
Tousseyn T, De Wolf-Peeters C (2011) T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification. Virchows Arch 459:557–563PubMedCrossRef
75.
Savage KJ, Skinnider B, Al-Mansour M et al (2011) Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 118:4585–4590PubMedCrossRef
76.
Eichenauer DA, Fuchs M, Pluetschow A et al (2011) Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 118:4363–4365PubMedCrossRef
77.
Bouabdallah R, Mounier N, Guettier C et al (2003) T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 21:1271–1277PubMedCrossRef
78.
El Weshi A, Akhtar S, Mourad WA et al (2007) T-cell/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma 48:1764–1773CrossRef
79.
Aki H, Tuzuner N, Ongoren S et al (2004) T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leuk Res 28:229–236PubMedCrossRef
80.
Park HC, Jung SH, Ahn JS et al (2012) Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma. Case Rep Oncol 5:413–419PubMedCrossRef
Metadaten
Titel
Lymphknotenpathologie – ein Update
verfasst von
Dr. S. Hartmann
M.L. Hansmann
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Die Pathologie / Ausgabe 1/2013
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-012-1706-5

Weitere Artikel der Ausgabe 1/2013

Der Pathologe 1/2013 Zur Ausgabe

Pitfalls

Siegelringzellhaltiges Infiltrat in der Kolon- und Magenschleimhaut

Schwerpunkt

Aktuelle medizinrechtliche und -ethische Herausforderungen der Pathologie

Mitteilungen

Mitteilungen

Fallberichte

Becherzellkarzinoid des Rektums

Mitteilungen

Pathologie ? Für das Leben und seine Qualität

Schwerpunkt

Molekularpathologie der Lunge

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise